D. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSEAMERICAN:OSTX)

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $20.00 price target on the stock.

Other research analysts have also issued reports about the stock. Lake Street Capital decreased their price target on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.50.

OS Therapies Trading Up 7.1%

Shares of OSTX opened at $1.36 on Thursday. OS Therapies has a 52 week low of $1.12 and a 52 week high of $2.98. The firm has a market cap of $47.89 million, a price-to-earnings ratio of -1.66 and a beta of -3.79. The stock has a 50 day moving average of $1.55 and a 200-day moving average of $1.83.

OS Therapies (NYSEAMERICAN:OSTX) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that OS Therapies will post -0.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OS Therapies

Hedge funds have recently modified their holdings of the company. CM Management LLC raised its stake in shares of OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $784,000 after buying an additional 25,000 shares in the last quarter. Millennium Management LLC acquired a new position in OS Therapies during the third quarter worth about $183,000. Two Sigma Investments LP bought a new stake in OS Therapies in the third quarter worth about $169,000. Virtu Financial LLC lifted its holdings in OS Therapies by 252.0% in the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after acquiring an additional 54,269 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of OS Therapies during the 2nd quarter valued at about $63,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.